Debunking the Immuno-Oncology Hype: is it as good as it sounds?

29/09/2016 - 5 minutes

CAR-T therapies have gained plenty of attention lately by promising to end cancer with a one-off treatment. But all that glitters is not gold; experts remind us it is important to be critical about the immuno-oncology hype.

Immuno-oncology has become all the rage lately, and the hype has led to some major investments, acquisitionsdeals and partnerships. It seems that the label “immuno-oncology” is sufficient to increase the value of the product. But Dr. Philip Greenberg, cofounder of Juno Therapeutics, a big Biotech developing CAR-T therapies, has called attention to the many challenges this field faces.

The first attempts to stimulate T-cells to attack tumors got the attention of big Pharma like Novartis, Kite Pharma and Juno Therapeutics. These companies are now advancing their programs in CAR-T, the breakthrough therapy that everyone’s after. In this treatment, the patient’s T-cells are engineered in vitro,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member